SUMO-modifying Huntington's disease

被引:12
|
作者
Soares, Ericks S. [1 ]
Prediger, Rui D. [1 ,2 ]
Brocardo, Patricia S. [2 ]
Cimarosti, Helena, I [1 ,2 ]
机构
[1] Fed Univ Santa Catarina UFSC, Postgrad Program Pharmacol, Florianopolis, SC, Brazil
[2] Univ Fed Santa Catarina, Postgrad Program Neurosci, Florianopolis, SC, Brazil
来源
IBRO NEUROSCIENCE REPORTS | 2022年 / 12卷
关键词
Huntingtin; Huntington's disease; Neurodegeneration; Post-translational modification; SUMO; SUMOylation; MUTANT-HUNTINGTIN; POSTTRANSLATIONAL MODIFICATIONS; PROTEIN; SUMOYLATION; RHES; AGGREGATION; DESUMOYLATION; DEGENERATION; PATHOGENESIS; DEGRADATION;
D O I
10.1016/j.ibneur.2022.03.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Small ubiquitin-like modifiers, SUMOs, are proteins that are conjugated to target substrates and regulate their functions in a post-translational modification called SUMOylation. In addition to its physiological roles, SUMOylation has been implicated in several neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases (HD). HD is a neurodegenerative monogenetic autosomal dominant disorder caused by a mutation in the CAG repeat of the huntingtin (htt) gene, which expresses a mutant Htt protein more susceptible to aggregation and toxicity. Besides Htt, other SUMO ligases, enzymes, mitochondrial and autophagic components are also important for the progression of the disease. Here we review the main aspects of Htt SUMOylation and its role in cellular processes involved in the pathogenesis of HD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [1] SUMO modification of Huntingtin and Huntington's disease pathology
    Steffan, JS
    Agrawal, N
    Pallos, J
    Rockabrand, E
    Trotman, LC
    Slepko, N
    Illes, K
    Lukacsovich, T
    Zhu, YZ
    Cattaneo, E
    Pandolfi, PP
    Thompson, LM
    Marsh, JL
    SCIENCE, 2004, 304 (5667) : 100 - 104
  • [2] DEVELOPMENT OF DISEASE MODIFYING THERAPIES IN HUNTINGTON'S DISEASE
    Bates, G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (10):
  • [3] Delivering a disease-modifying treatment for Huntington's disease
    Godinho, Bruno M. D. C.
    Malhotra, Meenakshi
    O'Driscoll, Caitriona M.
    Cryan, John F.
    DRUG DISCOVERY TODAY, 2015, 20 (01) : 50 - 64
  • [4] Disease modifying agents for Huntington's disease - What is on the horizon?
    Clarke, H
    Feigin, A
    CNS DRUGS, 1999, 12 (05) : 383 - 389
  • [5] Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease
    Corey-Bloom, Jody
    Jia, Haiqun
    Aikin, Alaina M.
    Thomas, Elizabeth A.
    JOURNAL OF HUNTINGTONS DISEASE, 2014, 3 (03) : 311 - 316
  • [6] Ubiquitin-modifying enzymes in Huntington's disease
    Sap, Karen A.
    Geijtenbeek, Karlijne W.
    Schipper-Krom, Sabine
    Guler, Arzu Tugce
    Reits, Eric A.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [7] Disease Modifying Agents for Huntington’s DiseaseWhat is on the Horizon?
    Hillary Clarke
    Andrew Feigin
    CNS Drugs, 1999, 12 : 383 - 389
  • [8] lmmunomodulation - a disease-modifying avenue for treatment of Huntington's disease?
    Bjorkqvist, Maria
    JOURNAL OF NEUROCHEMISTRY, 2016, 137 (05) : 670 - 672
  • [10] Translational research in Huntington's disease: Opening up for disease modifying treatment
    Burgunder J.-M.
    Translational Neurodegeneration, 2 (1)